Skip to main content
. 2019 Nov 25;10:1340. doi: 10.3389/fphar.2019.01340

Figure 3.

Figure 3

(A) The first dasatinib intake changes the proportion of CCR7 positive T-cells. Percentages of CCR7+ and CXCR4+ lymphocytes in CD4+ and CD8+ T lymphocytes are compared between paired samples collected before (PRE) and 2 h after (POST) the first dasatinib intake from DASAPOST patients (CCR7, n = 17;CXCR4, n = 13). Data are represented as dot plots with lines connecting samples corresponding to the same patient. (B) T- and B-cell subsets redistribute differently in response to dasatinib therapy. Percentages of naïve (CCR7+CD45RA+)(TN), CD45RA+ effector memory (CCR7-CD45RA+)(TEMRA) and central memory (CCR7+CD45RO+)(TCM) CD4+ and CD8+ T-cells in total CD4+ and CD8+ T-cells (upper panels) and total lymphocytes (middle panels) are compared between paired preintake and postintake samples collected before (gray bars) and 2 h after (black bars) the first dasatinib intake from DASAPOST patients (n = 12). Percentages of memory B-cells in total B-cells and total lymphocytes in the same cohort of patients are shown (lower panels). Data in (B) are represented as mean + SEM. Statistically significant p-adj values are shown on the graphs. ns, not significant.